JP2023554382A5 - - Google Patents
Info
- Publication number
- JP2023554382A5 JP2023554382A5 JP2023536348A JP2023536348A JP2023554382A5 JP 2023554382 A5 JP2023554382 A5 JP 2023554382A5 JP 2023536348 A JP2023536348 A JP 2023536348A JP 2023536348 A JP2023536348 A JP 2023536348A JP 2023554382 A5 JP2023554382 A5 JP 2023554382A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- cdr1
- cdr2
- cdr3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063126024P | 2020-12-16 | 2020-12-16 | |
| US63/126,024 | 2020-12-16 | ||
| PCT/US2021/063551 WO2022132923A1 (en) | 2020-12-16 | 2021-12-15 | Tau binding compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023554382A JP2023554382A (ja) | 2023-12-27 |
| JP2023554382A5 true JP2023554382A5 (https=) | 2024-12-19 |
Family
ID=80112434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023536348A Pending JP2023554382A (ja) | 2020-12-16 | 2021-12-15 | タウ結合化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240059766A1 (https=) |
| EP (1) | EP4263599A1 (https=) |
| JP (1) | JP2023554382A (https=) |
| KR (1) | KR20230157296A (https=) |
| CN (1) | CN117043183A (https=) |
| AU (1) | AU2021403010A1 (https=) |
| CA (1) | CA3205586A1 (https=) |
| IL (1) | IL303638A (https=) |
| MX (1) | MX2023007181A (https=) |
| TW (1) | TW202239765A (https=) |
| WO (1) | WO2022132923A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| KR20250069606A (ko) | 2022-09-15 | 2025-05-19 | 보이저 테라퓨틱스, 인크. | 타우 결합 화합물 |
| CN121773336A (zh) * | 2023-07-20 | 2026-03-31 | 拉亚·蒙托柳加亚 | P-tau免疫测定 |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| WO1994013795A1 (en) | 1992-12-14 | 1994-06-23 | N.V. Innogenetics S.A. | Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications |
| US6265389B1 (en) | 1995-08-31 | 2001-07-24 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of oligonucleotides |
| US6348584B1 (en) | 1996-10-17 | 2002-02-19 | John Edward Hodgson | Fibronectin binding protein compounds |
| EP1958962A3 (en) | 1997-06-12 | 2013-05-01 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| EP2319301B1 (en) | 2001-11-30 | 2017-09-06 | Amgen Fremont Inc. | Transgenic animals bearing human Ig lambda light chain genes |
| US7605249B2 (en) | 2002-11-26 | 2009-10-20 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
| AU2009298458B2 (en) | 2008-09-30 | 2015-10-08 | Ablexis, Llc | Non-human mammals for the production of chimeric antibodies |
| ES2984483T3 (es) | 2010-03-31 | 2024-10-29 | Ablexis Llc | Ingeniería genética de ratones para la producción de anticuerpos quiméricos |
| MY164376A (en) * | 2010-10-07 | 2017-12-15 | Univ Leuven Kath | Phosphospecific antibodies recognizing tau |
| KR101981351B1 (ko) * | 2011-10-07 | 2019-09-02 | 에이씨 이뮨 에스.에이. | 타우를 인식하는 포스포특이적 항체 |
| MX350311B (es) | 2011-12-20 | 2017-09-01 | Janssen Biotech Inc | Anticuerpos anti-phf-tau y sus usos. |
| NZ630542A (en) | 2012-08-16 | 2017-06-30 | Ipierian Inc | Methods of treating a tauopathy |
| CA2896066C (en) * | 2012-12-21 | 2022-07-12 | Biogen Ma Inc. | Human anti-tau antibodies |
| JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
| WO2019118906A2 (en) * | 2017-12-14 | 2019-06-20 | University Of Florida Research Foundation | Monoclonal antibodies targeting phf1 and at8 epitopes of human tau protein |
| SG11202008098TA (en) * | 2018-03-28 | 2020-10-29 | Axon Neuroscience Se | Antibody-based methods of detecting and treating alzheimer's disease |
-
2021
- 2021-12-15 CN CN202180093407.1A patent/CN117043183A/zh active Pending
- 2021-12-15 JP JP2023536348A patent/JP2023554382A/ja active Pending
- 2021-12-15 WO PCT/US2021/063551 patent/WO2022132923A1/en not_active Ceased
- 2021-12-15 EP EP21844118.6A patent/EP4263599A1/en active Pending
- 2021-12-15 MX MX2023007181A patent/MX2023007181A/es unknown
- 2021-12-15 AU AU2021403010A patent/AU2021403010A1/en not_active Abandoned
- 2021-12-15 CA CA3205586A patent/CA3205586A1/en active Pending
- 2021-12-15 TW TW110147015A patent/TW202239765A/zh unknown
- 2021-12-15 US US18/267,711 patent/US20240059766A1/en active Pending
- 2021-12-15 KR KR1020237024245A patent/KR20230157296A/ko active Pending
- 2021-12-15 IL IL303638A patent/IL303638A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023554382A5 (https=) | ||
| JP7453206B2 (ja) | 改良された血清アルブミン結合剤 | |
| JP6626892B2 (ja) | ヒト化抗タウ抗体 | |
| JP2023523401A5 (https=) | ||
| JP2025138634A (ja) | Ｂ細胞成熟抗原を標的にする多重特異性抗体のための投与計画及び組み合わせ治療 | |
| JP2024037893A (ja) | アルツハイマー病治療方法 | |
| IL300327A (en) | Treatment of diseases associated with colony-stimulating factor receptor 1 dysfunction using TREM2 agonists | |
| JP2019108359A (ja) | アテローム性動脈硬化の処置のためのセマフォリン−４ｄ結合分子の使用 | |
| JP2018519810A5 (https=) | ||
| JP2022541539A5 (https=) | ||
| CN105358175B (zh) | 用于治疗硬皮病的抗ccl2和抗loxl2组合疗法 | |
| JP2022538926A (ja) | Ｒａｎタンパク質関連神経学的疾患を処置するための方法 | |
| JP7109467B2 (ja) | タウに特異的に結合する結合分子 | |
| JP2019527194A5 (https=) | ||
| JP2009535021A5 (https=) | ||
| JP2018505651A5 (https=) | ||
| JP2018524370A5 (ja) | 抗ピログルタミン酸化アミロイドβヒト化抗体 | |
| CN115151562A (zh) | 用于治疗和诊断的新分子 | |
| JP2017525655A5 (https=) | ||
| TW202104255A (zh) | 用於治療及診斷之新穎分子 | |
| TWI717848B (zh) | 抗體於治療神經退化性疾病的用途 | |
| JP2020521745A (ja) | 治療用抗ｃｄ４０リガンド抗体 | |
| JP2023537761A5 (https=) | ||
| TW202328177A (zh) | 治療ｔａｕ病理學之方法 | |
| JP2025507569A5 (https=) |